Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Revisão |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
2014
|
| Mynediad Ar-lein: | https://doi.org/10.1517/14728222.2014.960843 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|